Evidence map›Paper›PMID 31466858›Full record

ArticleSurgery2019

Barriers to timely surgery for breast cancer in Rwanda.

Lauren E Schleimer, Jean-Marie Vianney Dusengimana, John Butonzi, Catherine Kigonya, Abirami Natarajan, Aline Umwizerwa, Daniel S O'Neil, Ainhoa Costas-Chavarri, Jean-Paul Majyambere, Lawrence N Shulman and 4 more

Abstract read
In one paragraph

Article in Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lauren E SchleimerDepartment of Surgery, Columbia University Medical Center, New York, NY.
Jean-Marie Vianney DusengimanaPartners In Health/Inshuti Mu Buzima, Rwanda.
John ButonziMinistry of Health, Butaro, Rwanda.
Catherine KigonyaPartners In Health/Inshuti Mu Buzima, Rwanda.
Abirami NatarajanMinistry of Health, Butaro, Rwanda; Department of Medicine, Harvard Medical School, Boston, MA.
Aline UmwizerwaPartners In Health/Inshuti Mu Buzima, Rwanda.
Daniel S O'NeilSylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Ainhoa Costas-ChavarriDepartment of Surgery, Rwanda Military Hospital, Kigali, Rwanda.
Jean-Paul MajyamberePartners In Health/Inshuti Mu Buzima, Rwanda.
Lawrence N ShulmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Nancy L KeatingDepartment of Medicine, Harvard Medical School, Boston, MA; Department of Health Care Policy, Harvard Medical School, Boston, MA.
Cyprien ShyiramberePartners In Health/Inshuti Mu Buzima, Rwanda.
Tharcisse MpungaMinistry of Health, Butaro, Rwanda.
Lydia E PaceDepartment of Medicine, Harvard Medical School, Boston, MA; Brigham and Women's Hospital, Boston, MA. Electronic address: lpace@bwh.harvard.edu.

Funding

Evaluating breast cancer care in rural RwandaK07CA215819 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI PACE, LYDIA · 2018 to 2023
$1.0M
NCI NIH HHS K07 CA215819
6 · The paper itself

Abstract

backgroundEnsuring timely and high-quality surgery must be a key element of breast cancer control efforts in sub-Saharan Africa. We investigated delays in preoperative care and the impact of on-site versus off-site operation on time to operative treatment of patients with breast cancer at Butaro Cancer Center of Excellence in Rwanda.

methodsWe used a standardized data abstraction form to collect demographic data, clinical characteristics, treatments received, and disease status as of November 2017 for all patients diagnosed with breast cancer at Butaro Cancer Center of Excellence in 2014 to 2015.

resultsFrom 2014 to 2015, 89 patients were diagnosed with stage I to III breast cancer and treated with curative intent. Of those, 68 (76%) underwent curative breast operations, 12 (14%) were lost to follow-up, 7 (8%) progressed, and 2 declined the recommended operation. Only 32% of patients who underwent operative treatment had the operation within 60 days from diagnosis or last neoadjuvant chemotherapy. Median time to operation was 122 days from biopsy if no neoadjuvant treatments were given and 51 days from last cycle of neoadjuvant chemotherapy. Patients who received no neoadjuvant chemotherapy experienced greater median times to operation at Butaro Cancer Center of Excellence (180 days) than at a referral hospital in Kigali (93 days, P = .04). Most patients (60%) experienced a disruption in preoperative care, frequently at the point of surgical referral. Documented reasons for disruptions and delays included patient factors, clinically indicated treatment modifications, and system factors.

conclusionWe observed frequent delays to operative treatment, disruptions in preoperative care, and loss to follow-up, particularly at the point of surgical referral. There are opportunities to improve breast cancer survival in Rwanda and other low- and middle-income countries through interventions that facilitate more timely surgical care.

Indexed as

Time-to-TreatmentAdultAgedAged, 80 and overBreast NeoplasmsChemotherapy, AdjuvantContinuity of Patient CareDelivery of Health CareFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingPreoperative CareReferral and ConsultationRetrospective Studies

Identifiers

PMID31466858
PMCPMC6861658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.